Heidelberg Pharma Expands Management Team

DGAP-News: Heidelberg Pharma AG

/ Key word(s): Personnel

01.03.2021 / 07:22

The issuer is solely responsible for the content of this announcement.

PRESS RELEASE

Heidelberg Pharma Expands Management Team

Dr. András Strassz promoted to Chief Medical Officer
– Dr. Mathias Locher joins to fill newly created position of Chief Development Officer

Ladenburg, Germany, 1 March 2021 – Heidelberg Pharma AG (FSE: HPHA) today announced the appointment of Dr. András Strassz as Chief Medical Officer and Dr. Mathias Locher as Chief Development Officer.

Dr. Strassz joined the company in April 2020 as Senior Medical Officer to build up the clinical development function. He has strong experience in clinical development, including in oncology. Dr. Strassz joined Heidelberg Pharma from Affimed, where he served as Medical Director. Previously, he held positions in clinical development at Sandoz and Amgen, among others. He holds both an MD and MBA from the University of Pécs, Hungary.

Dr. Locher has over 30 years of experience in drug development. He joins Heidelberg Pharma from Janssen (Pharmaceutical Companies of Johnson & Johnson), where he was Senior Director – External Innovation at the J&J London Innovation Centre. Prior to that, he held management positions at Covagen, Merck Serono, Micromet (now part of Amgen) and ASTA Medica. Dr. Locher holds a PhD in biochemistry from the University of Tuebingen.

Dr. Jan Schmidt-Brand, Chief Executive Officer and Chief Financial Officer of Heidelberg Pharma AG, commented: “I am very pleased that András Strassz and Mathias Locher are joining the Heidelberg Pharma management team. With our lead program, HDP-101, about to enter the clinic, we are evolving from a research organization to a clinical development company and with strengthening the team, we gain valuable know-how and necessary expertise. I look forward to working together with the growing team to achieve our goals.”

About Heidelberg Pharma
Heidelberg Pharma is an oncology company and the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary technology platform is being applied to develop the Company’s proprietary therapeutic ATACs as well as in third-party collaborations to create a variety of ATAC candidates. The proprietary lead candidate HDP-101 is a BCMA ATAC for multiple myeloma.

Heidelberg Pharma AG has entered into partnerships to further develop and commercialize its clinical assets upamostat (formerly MESUPRON(R)) and TLX250-CDx (formerly REDECTANE(R)). Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA. More information is available at www.heidelberg-pharma.com.

Contact
Heidelberg Pharma AG

Corporate Communications
Sylvia Wimmer
Tel.: +49 89 41 31 38-29
Email: investors[at]hdpharma.com
Gregor-Mendel-Str. 22, 68526 Ladenburg        
IR/PR support
MC Services AG
Katja Arnold (CIRO)
Managing Director & Partner
Tel.: +49 89 210 228-40
Cell: +49 (0)160 9360 3022
Email: katja.arnold[at]mc-services.eu
 

This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will” “should” “future”, “potential” or similar expressions or by a general discussion of the Company’s strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.


01.03.2021 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


show this